As of Apr 1, 2025, the Novartis AG stock's PE ratio is 18.52. This results from the current EPS of $5.92 and stock price of $109.61. The PE ratio has increased by 31% from the past four quarters average of 14.1.
The PE ratio of Novartis AG has averaged 19.85 over the last ten years. The current price-to-earnings ratio of 18.52 is 7% less than the historical average. In the past ten years, NVS's PE ratio reached its highest point in the Jun 2017 quarter at 30.35, when the stock price was $83.47 and the EPS was $2.75. The lowest point was recorded in the Sep 2022 quarter, when it reached 7.77 with a price of $76.01 and an EPS of $9.78.
Maximum annual increase: 248.1% in 2022
Maximum annual decrease: -69.29% in 2021
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 16.44 | 16.43% | $97.31 | $5.92 |
2023 | 14.12 | -50.35% | $100.97 | $7.15 |
2022 | 28.44 | 248.1% | $90.72 | $3.19 |
2021 | 8.17 | -69.29% | $87.47 | $10.71 |
2020 | 26.6 | 43.86% | $94.43 | $3.55 |
2019 | 18.49 | 17.25% | $94.69 | $5.12 |
2018 | 15.77 | -38.4% | $85.81 | $5.44 |
2017 | 25.6 | -0.89% | $83.96 | $3.28 |
2016 | 25.83 | 122.1% | $72.84 | $2.82 |
2015 | 11.63 | -47.16% | $86.04 | $7.4 |
2014 | 22.01 | 2.95% | $92.66 | $4.21 |
2013 | 21.38 | 29.34% | $80.38 | $3.76 |
2012 | 16.53 | 8.39% | $63.3 | $3.83 |
2011 | 15.25 | 10.75% | $57.17 | $3.75 |
2010 | 13.77 | -6.39% | $58.95 | $4.28 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 16.44 | 22.78% | $97.31 | $5.92 |
Sep 2024 | 13.39 | -1.11% | $115.02 | $8.59 |
Jun 2024 | 13.54 | 3.2% | $106.46 | $7.86 |
Mar 2024 | 13.12 | -7.08% | $96.73 | $7.37 |
Dec 2023 | 14.12 | -48.16% | $100.97 | $7.15 |
Sep 2023 | 27.24 | -2.3% | $101.86 | $3.74 |
Jun 2023 | 27.88 | -0.61% | $100.91 | $3.62 |
Mar 2023 | 28.05 | -1.37% | $92 | $3.28 |
Dec 2022 | 28.44 | 266.02% | $90.72 | $3.19 |
Sep 2022 | 7.77 | -5.47% | $76.01 | $9.78 |
Jun 2022 | 8.22 | 1.11% | $84.53 | $10.28 |
Mar 2022 | 8.13 | -0.49% | $87.75 | $10.8 |
Dec 2021 | 8.17 | -56.45% | $87.47 | $10.71 |
Sep 2021 | 18.76 | -18.15% | $81.78 | $4.36 |
Jun 2021 | 22.92 | -5.87% | $91.24 | $3.98 |
The current PE ratio of NVS is above its 3-year historical average, but it is lower than the 5 and 10-year averages.
NVS's PE ratio is less than its peer stocks JNJ and AZN, but it is above ABT's and MRK's. Novartis AG's current PE ratio of 18.52 is less than the average of its peers, which is 21.11.
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 12.89 | $220.07B |
ABT Abbott Laboratories | 17.17 | $228.39B |
PFE Pfizer Inc | 17.28 | $139.08B |
NVS Novartis AG | 18.52 | $216.49B |
JNJ Johnson & Johnson | 26.24 | $368.97B |
AZN Astrazeneca plc | 31.98 | $225.14B |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $17.34B |
BMY Bristol Myers Squibb Co | N/A | $120.85B |
NVS stock has a price to earnings ratio of 18.52 as of Apr 1, 2025.
The 3-year average PE ratio for NVS stock is 18.02.
The 5-year average PE ratio for NVS stock is 19.06.
Over the last ten years, the quarterly PE ratio reached a historic high of 30.35 in the Jun 2017 quarter.
NVS's price to earnings ratio is currently 7% below its 10-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Apr 1, 2025), Novartis AG's stock price is $109.61. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $5.92. Therefore, Novartis AG's price to earnings ratio for today is 18.52. PE RATIO(18.52) = STOCK PRICE($109.61) / TTM EPS($5.92)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.